13F Holdings
中文EN

EDSA Edesa Biotech, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1540159 · Fiscal year ends 09/30

Financial factors as of 2026-06-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-138.2%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-122.9%
ROA-102.5%
ROIC (approx.)-9,500.4%
Asset turnover—

Leverage & solvency

Liabilities / assets30.7%
Debt / equity0.00x
Current ratio2.76x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.63x
Accruals ratio-37.7%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-09-30FY20242024-09-30FY20232023-09-30FY20222022-09-30FY20212021-09-30
Income statement
Revenue————$0
Cost of revenue————$0
Gross profit————$0
R&D expense$3.67M$2.88M$4.79M$13.34M$17.95M
SG&A expense$4.24M$4.13M$4.43M$5.04M$5.73M
Operating income-$7.91M-$7.01M-$9.22M-$18.37M-$23.68M
Pretax income-$7.18M-$6.17M-$8.37M-$17.55M-$13.34M
Income tax$800$800$800$800$800
Net income-$7.19M-$6.17M-$8.37M-$17.55M-$13.34M
EBITDA-$7.79M-$6.83M-$9.04M-$18.25M-$23.56M
EPS (basic)-1.27-1.93-2.93—-1.10
EPS (diluted)————-1.10
Weighted avg. shares (diluted)————12.08M
Balance sheet
Cash & equivalents$10.79M$1.04M$5.36M$7.09M$7.84M
Receivables————$3.30M
Current assets$11.51M$1.68M$6.44M$9.09M$12.09M
PP&E, net—$0$8,702$12,694$14,989
Intangibles$1.98M$2.08M$2.18M$2.28M$2.38M
Total assets$13.53M$3.81M$8.89M$11.58M$14.58M
Current liabilities$1.08M$1.83M$1.82M$2.14M$1.46M
Total liabilities$1.08M$1.83M$1.84M$2.18M$1.53M
Shareholders' equity$12.45M$1.98M$7.05M$9.39M$13.06M
Shares outstanding7.14M3.25M3.08M2.38M13.30M
Cash flow statement
Operating cash flow-$7.32M-$4.89M-$6.64M-$12.28M-$13.66M
Capital expenditure——$0$5,656$6,146
Free cash flow——-$6.64M-$12.28M-$13.67M
Investing cash flow——$0-$5,656-$6,146
Financing cash flow$17.03M$592,031$4.83M$11.63M$14.17M
Depreciation & amortization$119,273$186,049$183,471$118,188$118,788
Stock-based compensation$729,642$537,492$1.25M$2.26M$3.20M

Free plan shows the latest 5 periods; Pro shows all 14 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.